scholarly journals APPLICATION OF JANUS-KINASE INHIBITORS IN THE TREATMENT OF ALOPECIA AREATA (LITERATURE REVIEW)

2019 ◽  
Vol 22 (1-2) ◽  
pp. 61-64
Author(s):  
Anfisa A. Lepekhova ◽  
L. M Chernyavskaya
Keyword(s):  
Literature Review ◽  
Mechanism Of Action ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Targeted Drugs ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated ◽  
Adults And Children

Based on the analysis of data from modern foreign sources current information about using of Janus-kinase inhibitors, in particular, tofacitinid and ruxolitinid, for the treatment of alopecia areata in adults and children, in the presence of a lesion of the scalp and other areas (eyebrows, eyelashes) is shown. The information about the mechanism of action of Janus-kinase inhibitors, the efficacy and safety of their use, possible methods of use, prospects for further research in the treatment of alopecia areata using targeted drugs is presented. The pathogenetic rationale for the possibility of using this group of drugs for treating immune-mediated diseases, for instance, alopecia areata is described.

JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease

2020 ◽  
Vol 21 (4) ◽  
pp. 247-255 ◽  
Author(s):  
Fabio Salvatore Macaluso ◽  
Iago Rodríguez-Lago
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Mechanism Of Action ◽  
Bowel Disease ◽  
Therapeutic Strategy ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Inflammatory Bowel

Background: Inflammatory bowel disease, including both Crohn’s disease and ulcerative colitis, are two chronic and progressive disorders affecting the gastrointestinal tract. Research on the molecular mechanisms of both diseases has led to the introduction of targeted therapies which are able to selectively block the key inflammatory mediators. Methods: Here, we discuss the current evidence about the mechanism of action with an up to date review of the efficacy and safety of Janus kinase inhibitors in inflammatory bowel disease. Results: Multiple small molecule drugs have been evaluated for their use in both ulcerative colitis and Crohn’s disease. Janus kinase inhibitors represent the most important family of these drugs, as their particular mechanism of action enables a simultaneous and effective blockade of multiple cytokines involved in the pathogenesis of the disease. Conclusion: Janus kinase inhibitors represent a promising therapeutic strategy, especially in ulcerative colitis. More data are still necessary regarding its efficacy and safety in clinical practice.

scholarly journals Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

2020 ◽  
Vol 80 (1) ◽  
pp. 71-87 ◽  
Author(s):  
Peter Nash ◽  
Andreas Kerschbaumer ◽  
Thomas Dörner ◽  
Maxime Dougados ◽  
Roy M Fleischmann ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Consensus Statement ◽  
Task Force ◽  
Inflammatory Diseases ◽  
Steering Committee ◽  
Janus Kinase ◽  
Expert Committee ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated

ObjectivesJanus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.MethodsExisting data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration.ResultsThe Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale.ConclusionThe consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.

scholarly journals Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review

2021 ◽  
Author(s):  
Pedro Jesús Gómez-Arias ◽  
Francisco Gómez-García ◽  
Jorge Hernández-Parada ◽  
Ana María Montilla-López ◽  
Juan Ruano ◽  
...  
Keyword(s):  
Scoping Review ◽  
Kinase Inhibitors ◽  
Type I Interferon ◽  
Janus Kinase ◽  
Type I ◽  
Efficacy And Safety ◽  
Autoinflammatory Disorders ◽  
Janus Kinase Inhibitors

The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review

2019 ◽  
Vol 32 (5) ◽  
Author(s):  
Ana B. Oliveira ◽  
Miguel Alpalhão ◽  
Paulo Filipe ◽  
João Maia‐Silva
Keyword(s):  
Systematic Review ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document